Nuvalent Announces First Patient Dosed in Heroex-1 Phase 1a/1B Clinical Trial of Nvl-330, Its Novel Her2-Selective Inhibitor
Nuvalent宣佈Nvl-330,其新型Her2選擇性抑制劑,進行Heroex-1 1a/10億臨床試驗中第一例患者劑量
Nuvalent Announces First Patient Dosed in Heroex-1 Phase 1a/1B Clinical Trial of Nvl-330, Its Novel Her2-Selective Inhibitor
Nuvalent宣佈Nvl-330,其新型Her2選擇性抑制劑,進行Heroex-1 1a/10億臨床試驗中第一例患者劑量
譯文內容由第三人軟體翻譯。